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Abstract
Background: EWS-FLI1 is a chimeric ETS transcription factor that is, due to a chromosomal rearrangement, specifically
expressed in Ewing’s sarcoma family tumors (ESFT) and is thought to initiate the development of the disease. Previous
genomic profiling experiments have identified EWS-FLI1–regulated genes and genes that discriminate ESFT from other
sarcomas, but so far a comprehensive analysis of EWS-FLI1–dependent molecular functions characterizing this aggressive
cancer is lacking.
Methodology/Principal Findings: In this study, a molecular function map of ESFT was constructed based on an integrative
analysis of gene expression profiling experiments following EWS-FLI1 knockdown in a panel of five ESFT cell lines, and on
gene expression data from the same platform of 59 primary ESFT. Out of 80 normal tissues tested, mesenchymal progenitor
cells (MPC) were found to fit the hypothesis that EWS-FLI1 is the driving transcriptional force in ESFT best and were
therefore used as the reference tissue for the construction of the molecular function map. The interrelations of molecular
pathways were visualized by measuring the similarity among annotated gene functions by gene sharing. The molecular
function map highlighted distinct clusters of activities for EWS-FLI1 regulated genes in ESFT and revealed a striking
difference between EWS-FLI1 up- and down-regulated genes: EWS-FLI1 induced genes mainly belong to cell cycle
regulation, proliferation, and response to DNA damage, while repressed genes were associated with differentiation and cell
communication.
Conclusions/Significance: This study revealed that EWS-FLI1 combines by distinct molecular mechanisms two important
functions of cellular transformation in one protein, growth promotion and differentiation blockage. By taking MPC as a
reference tissue, a significant EWS-FLI1 signature was discovered in ESFT that only partially overlapped with previously
published EWS-FLI1–dependent gene expression patterns, identifying a series of novel targets for the chimeric protein in
ESFT. Our results may guide target selection for future ESFT specific therapies.
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Introduction
Ewing’s sarcoma family tumors (ESFT), which comprise
Ewing’s sarcoma, peripheral primitive neuroectodermal tumors,
and Askin tumor, are undifferentiated small blue round cell tumors
affecting children and young adults as the second most frequent
bone cancer [1]. This highly aggressive cancer is characterized by
a chromosomal translocation that results in the formation of a
gene fusion between the EWSR1 locus and an ETS transcription
factor gene, which in 85% of the cases is FLI1 [2]. EWS-ETS
fusion genes encode aberrant transcription factors which are
thought to be rate-limiting for ESFT pathogenesis [3]. Using
different model systems the functional consequences on gene
expression of EWS-FLI1 have recently been studied in whole
genome gene expression profiling analyses, and the target gene sets
were compared to deregulated genes in ESFT to test for biological
relevance (see [4] for a review). In this study we follow this
approach, but while previous reports mostly focused on the
functional relevance of single selected target genes, we aimed at
analyzing the molecular function of EWS-FLI1 regulated genes in
ESFT on a pan-genomic level. Therefore we highlighted classes of
genes, rather than single genes that appear to be crucial for the
development of ESFT and consequently deserve to be studied in
more detail.
In the absence of knowledge about the tissue of origin for ESFT,
previous studies measured EWS-FLI1 regulated gene expression
relative to either other sarcomas [5,6] or a mean of different
normal tissues [6,7]. Tirode et al. [8] recently showed that the
profiles of different EWS-FLI1-silenced ESFT cell lines converge
toward that of mesenchymal progenitor cells (MPC). Furthermore,
it was shown that EWS-FLI1 induces a gene expression profile in
human MPC that resembles that of ESFT [9] and that EWS-FLI1
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mal progenitor cells and induce ESFT resembling tumors in mice
[10,11]. Here, we demonstrate that using MPC as reference tissue
best fits the model that EWS-FLI1 is the major driver for the gene
expression signature of ESFT.
Results
Defining a reference tissue for ESFT
In order to construct a molecular function map of ESFT,
information about EWS-FLI1 regulated genes was combined from
two sources using the same microarray platform. On the one hand
consistently altered gene expression after 96 hours EWS-FLI1
knock down by fusion type specific shRNA [12] was determined in
5 ESFT cell lines (TC252, STA-ET-1, WE68, STA-ET-7.2, SK-
N-MC), the largest panel of ESFT cell lines used for this purpose
so far. On the other hand, genes were identified that are
consistently de-regulated in a panel of 59 primary ESFT. To
assess de-regulation of genes in ESFT, gene expression has to be
compared to a reference tissue, the choice of which critically
influences the results. However, the tissue of origin of ESFT,
which would be the ideal reference, is not known. The assumption
that most gene expression aberrations in ESFT with respect to the
cell of origin are triggered by EWS-FLI1 provides a model with
which it is possible to test the quality of any reference tissue. More
specifically, gene expression differences between ESFT and the
reference tissue (DET) are expected to be inversely correlated with
the gene expression differences between EWS-FLI1 knockdown
and control (DKD). Therefore, by maximizing this expected
correlation we searched for the tissue which fits the model
assumption best. To this end we compared gene expression
differences between primary ESFT and all 79 tissues in the
Novartis gene expression atlas [13] as well as a set of recently
published MPC data from two sources [8,14], and subsequently
searched for the tissue that maximizes the inverse correlation with
the gene expression change after a EWS-FLI1 knockdown. We
found that, while the correlations were generally biased towards
negative values (Figure 1), the highest inverse correlation was
found for the comparison of DKD with DET from the comparison
of ESFT with MPC as reference tissue (DET[MPC],r = 20.5).
Hence using a different analytical approach, we corroborated the
findings of Tirode et al. [8] with data from more than twice as
many primary ESFT and more cell line models.
In Figure 2 the intersection of the most significant genes
(FDR,0.1, see below and Methods) from DET and DKD is
plotted against each other using either the mean of all tissues
(Figure 2A) or MPC (Figure 2B) as a reference. In Figure 2A many
genes do not conform to the expectation for EWS-FLI1 regulated
genes since they are repressed by EWS-FLI1 but expressed at a
higher level in the tumors than in the reference (upper right
quadrant). In contrast, almost all genes conform to the hypothesis
in Figure 2B. Here, the inverse correlation with knockdown data
improves from 20.38 for the ESFT-mean tissue comparison to
20.84 for the ESFT-MPC comparison. The increased correlation
fits the model of comparing ESFT gene expression to the
appropriate base level of the presumptive tissue of origin.
Therefore, for all further analyses we chose MPC as gene
expression reference for ESFT.
Defining EWS-FLI1 target genes
Genes consistently regulated by EWS-FLI1 in cell line models
and primary tumors were identified by applying thresholds of
different stringencies to the two gene lists (adjusted P-value cutoffs:
0.1 and 0.25, gene sets ‘‘GS1’’ and ‘‘GS2’’, respectively. For
details, see Materials and Methods section). Furthermore, a small
fraction of genes that did not follow the inverse correlation
between DKD and DET by falling into the upper right and lower
left quadrants of Figure 2B were excluded. The percentage of such
genes corresponded to ,6% in GS1 and ,12% in GS2. In the
framework of our starting hypothesis these genes likely represent
false positives and therefore their percentage can be used as
empirical estimates of the false discovery rate in GS1 and GS2. It
can, however, not be excluded that in the enigmatic tissue of ESFT
origin, which according to our data should be very close to MPC,
these few outlier genes may in fact behave according to the
hypothesis. Applying these criteria we found 237 and 344 (GS1)
genes to be consistently up- and downregulated in the EWS-FLI1
knockdown cell lines, and repressed and activated in primary
tumors at a FDR,,0.06. For GS2, 731 and 463 genes were
identified as EWS-FLI1 up- and down-regulated (FDR,,0.12).
The complete lists comprising results for all genes from the analysis
of differential expression can be found in Table S1.
Comparison of EWS-FLI1 target genes to literature data
The gene sets GS1 and GS2 were compared to a recently
published ‘‘core EWS-FLI1 gene expression signature’’ [4]. As a
result we found that, while the data sets significantly overlap
(P,10e-20, hypergeometric test), most genes in this earlier gene
expression signature fall below the significance threshold (of either
DET or DKD) in our data, and we identified many additional
genes as EWS-FLI1 regulated even using the stringent gene set
GS1. Overall 457 of the up- and 198 down regulated genes in the
Hancock data set were present in our data set of 7034 genes. Out
of these, 115 and 50 genes overlapped with GS1 and 181 and 75
with GS2.
The data were also compared to a recently published set of
putative direct binding targets of EWS-FLI1 as determined by
ChIP-on-chip [15]. Only 19 (5.5%) and 7 (2.9%) of the 903
putative direct binding targets were found in the up- and down-
regulated genes of GS1. In GS2 these numbers are 28 and 16
(3.8% and 3.5%) which is similar to the overlap with the Hancock
gene set: 23 and 11 genes (3.9% and 3.8%) although different
genes are affected.
A molecular function map of EWS-FLI1 target genes
A molecular function map of EWS-FLI1 target genes was
constructed by annotating the stringent set of EWS-FLI1 regulated
genes defined above (GS1) using data bases of gene-function
relationships. Gene annotations in these data bases are highly
redundant and therefore we followed a two tiered strategy: first
annotations significantly enriched in the EWS-FLI1 signature were
identified, and then these different functional groups were
aggregated into a map by using the number of shared genes as
similarity criterion (gDist, see Methods).
Functional groups (FG) of gene annotations in the 344 EWS-
FLI1 up- and 237 down-regulated genes of GS1 were identified
using ‘‘The Database for Annotation, Visualization and Integrated
Discovery’’ (DAVID) [16]. The full output of this analysis can be
inspected in Table S2, S3. To construct a map of molecular
functions, the interrelations between the 25 most significant FGs
were explored by multidimensional scaling (MDS) (Figure 3A and
3C) and hierarchical clustering using gDist (Figure 3B and D). To
improve the visualization of the clustering results, broadly defined
general FGs consisting of more than 200 genes were omitted in
this analysis (i.e. FG1, FG3 and FG10 in Table S2).
For the EWS-FLI1 up-regulated gene set (Figure 3A and 3B) the
largest molecular function group is FG-2 - ‘‘mitotic cell cycle’’ -
which comprises five more FGs that share the same center in the
Molecular Function Map of ESFT
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with a cell cycle related function. Cell cycle thus represents the
major hub of molecular functions for EWS-FLI1 up-regulated
genes. The central role of this functional group can also be seen in
the heatmap (Figure 3B) which shows that FG-2 is the group that is
most highly connected by gene-sharing (highest values of gDist) to
other FGs. The second most connected FG is FG-6 - ‘‘macromo-
lecular complex’’. Only three functional groups are located very
far apart from FG-2 (and FG-6) in gene space, the largest of which
is FG-17 – ‘‘mitochondrion’’ which shares most genes with FG-18
and FG-21 (both ‘‘biosynthetic process’’). Two additional
prominent (sub-) clusters can be discerned in the heatmap
comprising FG-6, -15, -22 and -24, and FG-11, -4, -16 and -25.
FG-20 (‘‘Interpro motif HEAT’’) and FG-25 (‘‘NIBRIN’’) are
small specific groups and both are only marginally significant
(Table S2). FG-20 comprises 8 genes which contain the ‘‘HEAT
repeat’’ which is found in cytoplasmic proteins that may be
involved in intracellular transport processes. FG-25 consists of
seven genes (MSH2, RFC4, MSH6, PRKDC, RMI1, CCND1,
CCNB1) which interact with at least one of: NIBRIN (NBS2),
RAD50, BLM, RFC1, MLH1, MRE11 or BRCA1. All of these
seven proteins are annotated to be bound by MSH2, RFC4 and
MSH6. These are the most significant protein interactions found
for upregulated genes, and the most significant annotation of this
group is ‘‘DNA-repair’’ and ‘‘response to DNA damage stimulus’’.
The only other significantly enriched protein-interaction term was
p21 (CDKN1A) which is found in FG-23 (interacting genes from
GS1: CDC7, CCNB2, CCND1, CCNB1). To address the
question whether the down regulation of cell cycle related genes
might result from an indirect effect of a growth arrest of cell lines
after the knockdown of EWS-FLI1 we performed a DAVID
analysis of significantly downregulated genes (P,0.01 after
Benjamini-Hochberg correction) from the earliest (18 hours after
knockdown) time point of a Doxicyclin inducible knockdown of
EWS-FLI1 in A673 cells. GO:0007049 (cell cycle) was identified as
highly significantly overrepresented in this gene set (P=1.3E-10)
with 72 genes annotated in this category (data not shown).
The molecular function map for the EWS-FLI1 down-regulated
genes shows two main clusters. On the right in Figure 3C the main
functional group is FG-8 – ‘‘signal’’. This group completely
comprises FG-6, ‘‘extracellular region’’, and seven other FGs are
located in close proximity. Gene sharing between all of these
groups is very high (Figure 3D). Three of these groups contain cell
adhesion related genes and one group integrin binding genes. FG-
9 consists of 15 genes which either contain the VWC domain
which is found in proteins that form multiprotein complexes and/
or which are involved in polysaccharide binding, glycosaminogly-
can binding or heparin binding. The main functions of these genes
are again cell adhesion, migration, homing, pattern formation, and
signal transduction. On the left side of Figure 3C, FG-1 and FG-2,
which share ,75% of the genes, represent the main functional
groups. Apoptosis (FG-5 ‘‘death’’) related genes, blood vessel
development (FG-4) are comprised within FG-2, and FG-7 is a
subset of FG-1 but shares also 95% of the genes with FG-2. FG-7
contains not only five genes with an IGFBP related protein
domain (CRIM1, IGFBP3, CTGF, HTRA1, CYR61) but more
generally also genes involved in cell growth and morphogenesis.
FG-14 is the only other larger functional group. It contains genes
with functions related to ‘‘response to stress’’, ‘‘blood coagulation’’,
‘‘response to wounding’’ and clusters with FG-21 and FG-18. In
FG-18 members of the p53 (KEGG) and p53-hypoxia (Biocarta)
pathway are found (CDKN1A, DNAJB1, FHL2, GADD45A,
GADD45B, IGFBP3, NQO1, SERPINE1 and THBS2) and also
interactions of these genes among each other and with other
proteins mainly of the p53 pathway: TP53, E1A, GADD45A,
MAPK8, FLH2, IGFBP3, BAX, RPA1, ABCB1, TAF1. Apart
Figure 2. DKD-DET plot. Plot of relative gene expression values of the EWS-FLI1 knockdown compared to control (DKD, x-axis) and ESFT compared
to reference (DET, y-axis). (A) reference=the mean of all tissues in the Novartis gene expression atlas, (B) reference=human mesenchymal progenitor
cells (MPC). Genes for this plot were selected by applying an adjusted p-value cut-off: P,0.1 for DKD and DET. The Pearson correlation coefficients (R)
between DKD and DET are indicated in the boxes.
doi:10.1371/journal.pone.0005415.g002
Figure 1. Plot of Pearson correlation coefficients of corr(DET, DKD). For each reference tissue tested (y-axis) the correlation coefficient
between DET[ref] and DKD is shown (x-axis). While the distribution of correlation coefficients is generally skewed towards negative values the highest
negative correlation is found for corr(DET[MPC], DKD).
doi:10.1371/journal.pone.0005415.g001
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mediates protein-protein interactions) containing genes are found
in GS1 (LIMS2, LPP, CSRP2, PDLIM2, FHL2, LIMA1) which
are collected in FG-23. Another protein domain that is
overrepresented in the EWS-FLI1 down regulated gene set is
the Leucine-zipper which is represented in FG-15 where 11 genes
with transcription factor activity (FOSL2, BACH1, MAFF, ATF3,
FOSL1, XBP1, CEBPD, TSC22D3, EPAS1, TCF7L1, TCF7L2)
are combined, three of these from the Wnt pathway. One of the
most significant molecular function groups of EWS-FLI1 repressed
genes is FG-3 which combines genes involved in chelation/metal
ion binding and acetylation. Interestingly the whole Metallothio-
nein cluster on chromosome 16q13 is found on the down regulated
side of GS1.
To examine the relationship of the EWS-FLI1 deregulated gene
signature with publically available data sets we searched a large
database of molecular signatures (MSigDB available from the
Broad Institute (http://www.broad.mit.edu/gsea/msigdb/ Cam-
bridge, USA) for significant overlap with EWS-FLI1 deregulated
genes using an approach (pGSEA) that does not require applying a
P-value threshold to filter for significant genes prior to the analysis
[17–19]. The MSigDB database consists of five different gene
collections: i) C1: positional gene sets, ii) C2: curated gene sets
from canonical pathways and experimental data, iii) C3: DNA
motif gene sets for transcription factor and miR binding sites, iv)
C4: computational gene sets and v) C5: GO terms. C1–C3 were
used in this analysis. In contrast to the DAVID analysis where a
pre-defined gene set was tested (GS1), the input for pGSEA was
the whole filtered expression data set (7034 genes – Table S1), and
DET and DKD were tested independently from each other.
Despite testing DET and DKD independently we found that
significantly scoring gene sets from MSigDB (P,10e-4) were
almost always expressed in opposite directions in the two
experimental data sets consistent with our starting hypothesis
about the inverse correlation of DET and DKD (Table S4).
Overall, at a stringent P value cutoff of P,10e-4, 16 MSigDB gene
sets were found to be significant for c1 (3 DKD/DET down/up, 13
DKD/DET up/down), 142 for c2 (96 DKD/DET down/up, 46
DKD/DET up/down) and 55 for c3 (30 DKD/DET down/up, 25
DKD/DET up/down). Lists of all significant MSigDB datasets,
the respective pGSEA statistics and the contributing genes can be
found in Table S4.
The similarity among the significant MSigDB gene collections
was further explored by identifying the ten most significant gene
sets from c2 and c3 by their combined z-score (see Methods), and
their proximity in gene space was determined using gDist. The
resulting distance matrix was used for hierarchical clustering of the
MSigDB gene sets (Figure 4). The emerging picture for EWS-FLI1
up- versus down-regulated gene sets was very different. In the up-
regulated class (Figure 4A) one large cluster could be found
comprising the majority of the 20 tested MSigDB gene sets except
the ones with E2F binding motifs, which formed the second
cluster, and two gene sets that were found to be up-regulated in
ESFT in earlier studies [20,21], which form a separate group. For
the down-regulated class on the other hand (Figure 4B) the
molecular signatures from MSigDB showed very little clustering.
As discussed below this finding might hint to a more complex
transcription-regulatory network acting upstream of the EWS-
FLI1 down-regulated than of EWS-FLI1 up-regulated genes.
Discussion
EWS-ETS gene fusions (predominantly EWS-FLI1) are associ-
ated with at least 95% of ESFT. They sometimes occur as the only
detectable genetic aberration in this disease and are therefore
assumed the major driver of aberrant gene expression in ESFT
[3]. Consequently, EWS-FLI1 is considered the ideal target for
future ESFT treatment strategies [22]. While it is still difficult to
directly target aberrant transcription factors, intervention into
EWS-FLI1 driven downstream pathways may be feasible. Since it
is unlikely that ESFT pathogenesis solely depends on the function
of single EWS-FLI1 target genes, this study was performed to
define on a pan-genomic level EWS-FLI1 driven functional
pathways in ESFT. It has previously been reported that the EWS-
FLI1 transcriptional target spectrum depends on the cellular
context [3,23,24]. Thus, the identification of EWS-FLI1 regulated
genes and pathways relevant to ESFT pathogenesis critically
depends on the choice of the reference tissue. Most previous
studies of ESFT expression profiles used sarcomas or the mean of
different normal tissues for reference [5–7]. Guided by the
hypothesis that upon malignant conversion of the still enigmatic
ESFT progenitor cell most of the expression changes should be
related to the presence of EWS-FLI1, and therefore genes that are
repressed/activated after EWS-FLI1 silencing in the cell lines
should be expressed at higher/lower levels in primary ESFT than
in the appropriate reference tissue, we found that MPC best fit this
assumption. Using the largest panel of EWS-FLI1 knockdown cell
lines reported so far and doubling the number of primary tumors
in the analysis, our data support the conclusions of Tirode et al.
about the possible relation of ESFT to mesenchymal progenitor
cells [8]. Using MPC as reference and selecting genes that were
differentially expressed (FDR,0.1, GS1) in both data sets (DKD
and DET) only a small subset (,6%) of genes was found not to
follow the theoretical expectation.
To assess the consequences of choosing MPC as reference tissue
for ESFT gene expression, we checked for genes that were defined
in earlier studies as putative EWS-FLI1 targets. We found that the
overlap with a recently published EWS-FLI1 signature [4] was
significant, but ,70% of the genes at a p-value cut-off of 0.1 (GS1)
and ,80% at a stringency threshold of 0.25 (GS2) were not
present in this earlier data set. Conversely, ,75% (overlap with
GS1) and ,60% (overlap with GS2) of the Hancock 2007
signature were not found in our study. This is illustrated in Figure
S2 which shows the distribution of DKD and DET values for all
genes from the Hancock signature. Genes that were not included
in GS1 or GS2 did not show a significant p value for DKD or
DET, and therefore they are located around the intersection of the
zero-lines in the Figure. Still, however, most genes that were found
Figure 3. Molecular Function Map of ESFT. Functional groups (FG) from the DAVID analysis were aggregated by multidimensional scaling (MDS
– A: EWS-FLI1 upregulated genes and C: EWS-FLI1 downregulated genes) and hierarchical clustering (B: EWS-FLI1 upregulated genes and D: EWS-FLI1
downregulated genes). In the MDS plots the x- and y-axis represent the first two dimensions of the MDS procedure (see Materials and Methods for
details). Circles indicate the relative size (number of genes) of the annotation clusters. FGs with more than 60 genes are shown as solid circles, smaller
FGs as dashed circles. The number of genes within each FG is indicated after the hyphen. The intersections of the circles are determined by their
position in the plot and their size only and do not quantify the number of shared genes. However, FGs (circles) which share the same center indicate
that the smaller gene set is a subset of the larger gene set. The heatmaps (B, D) show a hierarchical clustering (average linkage algorithm) of the FGs
using the number of shared genes as distance measure (gDist – see Methods). Red indicates highest similarity (the smaller gene set is a subset of the
larger one) and white the lowest similarity (no shared gene). Intermediate values for gDist are indicated as shades of orange/yellow.
doi:10.1371/journal.pone.0005415.g003
Molecular Function Map of ESFT
PLoS ONE | www.plosone.org 6 April 2009 | Volume 4 | Issue 4 | e5415Figure 4. Significant MSigDB gene sets. Significant MSigDB gene sets (c2, c3) from the pGSEA analysis were aggregated by hierarchical
clustering. A: Gene sets significantly overlapping EWS-FLI1 upregulated genes, B: Gene sets significantly overlapping EWS-FLI1 downregulated genes.
doi:10.1371/journal.pone.0005415.g004
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are found in the upper left quadrant of Figure S2A, while most
genes that were found to be down-regulated by EWS-FLI1 in the
previous study are found in the lower right quadrant of Figure
S2B. Thus, even though not significant in our analysis, the
majority of the Hancock signature genes tend to conform to the
underlying hypothesis of our study of EWS-FLI1 being the major
driver of aberrant gene expression in ESFT, despite the usage of
different reference tissues. A DAVID analysis on the Hancock
signature genes revealed that they annotate preferentially to
identical functional categories as identified in our study (not
shown). Consequently, the two EWS-FLI1 signatures gradually
differ with respect to their significance levels but not in their
functional assignments. Therefore, in Table S1 DKD and DET
values are provided for all genes and any gene can be assessed in
relation to the rank order of all other genes that were studied here.
Ranking the genes by their combined log2 fold change
(DSUM=abs(DKD)+abs(DET)) identified PRKCB1, NR0B1,
NKX2-2, BCL11B, KMO, OPN3, PPP1R1A, PKP1, DAPK1, CCK,
TRPM4 (EWS-FLI1 up-regulated) and RND3, PTX3, LOX, TFPI2,
ADM, TAGLN, DAB2, SRPX, GADD45B (EWS-FLI1 repressed) as
the 20 top EWS-FLI1 regulated genes. However, only 11 of these
are found in the Hancock signature. On the other hand most of
these genes are classified as high ranking in the Tirode data set [8]
(Table S2), which is expected as the present study was similarly
designed, however with more data from primary tumors and cell
lines. Furthermore, some genes that were reported as putative
‘‘bona fide’’ targets of EWS-FLI1 in ESFT are not found in the
highest ranking gene set in our study. From a list of earlier
identified EWS-FLI1 target genes which were also biochemically
studied in some detail (CAV1 [25], DKK1 [26,27], ID2 [28], IGF1
[29], IGFBP3 [30], MAPT [20], NKX2-2 [31,32], NR0B1 [15,33],
PDGFC [34], PLD2 [35], PTPN13 [36], STEAP1 [31], TGFBR2
[37], TERT [38], UPP1 [39]), 33% (CAV1, ID2, IGF1, PLD2 and
TERT) were neither found in GS1 nor in GS2. These genes rank
at positions 1322, 1590, 847, 4437 and 5482 of the whole gene list,
respectively (Table S1, sheet1 ranked by DSUM).
Of note, most of the above so far in-depth studied genes,
regardless whether EWS-FLI1 up- or down-regulated, are mainly
annotated to be involved in signaling, morphogenesis, develop-
ment and other more specialized functions. When compared to
the molecular function map developed in this study (Figure 3)
these annotations overlap with only a subset of the molecular
functions of EWS-FLI1 deregulated genes. In contrast, the
majority of EWS-FLI1 activated genes relate to cell cycle and
functions that are needed for the cell to proliferate at a high rate
(‘‘mitochondrion’’, ‘‘rRNA processing’’, ‘‘biosynthetic process’’,
etc). Furthermore, the most significant protein interactions in the
data suggested that DNA-repair complexes are activated by EWS-
FLI1. The almost exclusive enrichment of E2F sites in up-
regulated genes might hint to a special importance of E2F
transcription factors in EWS-FLI1 mediated proliferation control.
On the other hand, genes that are known to function in cell
differentiation, morphogenesis and the formation of differentiated
tissues were generally down-regulated by EWS-FLI1, consistent
with the poorly differentiated ESFT phenotype. Thus it appears
that EWS-FLI1 combines two key functions in oncogenic
transformation, proliferation stimulation and suppression of
differentiation, in one protein, but by distinct mechanisms.
Based on our results, one would expect that introduction of
EWS-FLI1 into MPC or mesenchymal cell lines should also result
in a cell cycle signature. While this was the case for the human
fetal fibroblast cell line IMR90 [40], DAVID annotation of
signature genes in human MPC cultures with ectopically expressed
EWS-FLI1 did not highlight enrichment of cell cycle or related
functions consistent with the reported lack of any change in the
proliferation rate of these cells [9]. We can only speculate about
the possible reasons for this apparent discrepancy to the EWS-
FLI1 knock-down models and ESFT tumors. It may be related to
the in-vitro culture conditions for the expansion of MPC.
Another difference of EWS-FLI1 up- and down-regulated classes
of genes in ESFT was revealed in the pGSEAanalysis of the MSigDB
signatures. MSigDB gene collections overlapping with EWS-FLI1
up-regulated genes showed relatively strong clustering due to the
similarity of the respective gene sets, while down-regulated genes
showed only little overlap. Thus MSigDB gene collections enriched
for EWS-FLI1 up-regulated genes, despite being derived from
different sources, seem to belong to a functional class that is
characterized by a relatively invariant gene set, while MSigDB
signatures enriched for EWS-FLI1 down-regulated targets are more
variable in gene composition. The analysis of the motif gene sets (C3)
shows this pattern most clearly: While for the EWS-FLI1 up-
regulated genes only enrichment of E2F, NRF1, NFY motifs was
found, a wide variety of DNA sequence motifswas identified in EWS-
FLI1 down-regulated genes. This finding suggests a more complex
transcription-regulatory network acting upstream of the EWS-FLI1
down-regulated than of EWS-FLI1 up-regulated genes,and raises the
question, in how far and in which way EWS-FLI1 directly controls
gene regulation by directly binding to its targets. Previous in-vitro
studies identified EWS-FLI1 as an activating transcription factor
[41,42]. Thus, one would expect more direct EWS-FLI1 targets
among activated than among repressed genes, and our data suggest
that these predominantly map to cell cycle and proliferation control.
In this respect, the association of EWS-FLI1 activated genes with E2F
motifs in C3 may be of interest. Surprisingly, only 5.5% of the EWS-
FLI1 up-regulated genes and 2.9% of the down-regulated genes in
GS1 are represented among directly bound genes in a recently
published EWS-FLI1 ChIP-on chip study [15]. Whether this low
frequency of gene discoveryreflects either a tight spectrum of genes in
thetoplayerof the EWS-FLI1targetgene hierarchy or may bedue to
methodological limitations, or suggest a transcription-independent
mechanism in EWS-FLI1 mediated gene regulation remains to be
established in future studies.
The pGSEA analysis of the MSigDB collection C1 revealed a
positional bias for EWS-FLI1 regulated genes with respect to
chromosomal localizations. Increased expression in ESFT versus
MPC was generally found to be enriched on chromosomes 8, 14,
17, 19, and 22, especially at the terminal regions, and to a lesser
extent on chromosomes 12, 13 and 20. Two chromosomal regions
deserve special attention: 8q24, the region comprising the MYC
locus, was found over-expressed, and 16q12–13 showed significant
under-expression. Both chromosomal regions are frequently
involved in numerical aberrations in ESFT. Trisomy 8 occurs in
about 50% of cases, and losses of 16q are frequently observed in
ESFT due to unbalanced rearrangements with chromosome 1,
and are associated with poor outcome [43]. While it cannot be
excluded that the observed enrichment for chromosome 8
encoded genes is a consequence of a high content of chromosome
8 amplified tumors in the investigated ESFT series, it should be
noted that chromosome 8 was also enriched in a previous EWS-
FLI1 ChIP-screening study [44], suggesting that increased
expression of this genomic region might be driven by EWS-FLI1
and is amplified by chromosome duplication. Also, under-
expression of 16q12–13 cannot easily be explained by chromo-
somal deletion, since several of the genes under-expressed in ESFT
were found to be significantly induced upon knockdown of EWS-
FLI1 and were therefore found in GS1 and GS2 (i.e. MMP2,
AKTIP, CYLD ), while others remained unchanged (i.e. ZNF423,
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chromosome 16 were found in 16q13 (Figure S2) which was
therefore identified as significant in the pGSEA analysis. Here,
functional annotation revealed enrichment of ‘‘chelation/metal
ion’’, which is due to the fact that all metallothionein genes reside
in this region. Since these proteins have previously been implicated
in cancer [45,46], their suppression in ESFT may deserve in-depth
functional studies in the future. Two further genes from this
region, HERPUD1 and ARL2BP, were also found suppressed,
while NUP93, which separates them from the metallothionein
cluster, showed slightly higher expression in ESFT than in MPC.
In summary, our data are consistent with a mesenchymal
progenitor cell origin of ESFT and suggest a dual role of EWS-
FLI1 in ESFT pathogenesis: the activation of cell cycle and
proliferation promoting genes and the repression of differentiation.
Our results may guide target selection for future molecular
therapeutic intervention strategies in ESFT.
Materials and Methods
Cell lines
All ESFT cell lines used in this study have previously been
described [47,48]. Cell lines WE68, SK-N-MC, and TC252 were
kindly supplied by F. Van Valen (Dept. of Pediatrics, University of
Muenster, Germany), J. Biedler (Memorial Sloan-Kettering
Cancer Center, New York, USA), and T. Triche (Dept. of
Pathology, Children’s Hospital, Los Angeles, USA), respectively.
The STA-ET-1 and STA-ET-7.2 cell lines were established at the
Children’s Cancer Research Institute (Vienna, Austria).
RNA interference
Cells were transfected with LipofectAMINE Plus reagent (Invitro-
gen, Groningen, The Netherlands) and subjected to puromycin
selection (1 mg/mL) the next day. On day 4 after transfection,
puromycin selected cells were processed for RNA and protein
extraction. SiRNAs against the fusion regions of type 1 (EF30) in
TC252, WE68, SK-N-MC, STA-ET-1, and type 2 (EF22) EWS-
FLI1 in STA-ET-7.2 wereexpressed as smallhairpin (sh) RNAs from
pSUPER-based retroviral expression constructs as previously de-
scribed [12]. For negative control, pSTNeg (Ambion, Applied
Biosystems, Brunn am Gebirge, Austria) encoding a scrambled
shRNA with no significant similarity to human sequences was used.
Gene expression analysis by microarray technology
Changes in gene expression profiles upon knockdown of EWS-
FLI1 were followed on Affymetrix HG-U133A arrays (Affymetrix,
Inc., Santa Clara, CA). cRNA target synthesis and GeneChipH
processing were performed according to standard protocols
(Affymetrix, Inc., Santa Clara, CA). All further analyses were
performed in R statistical environment using Bioconductor
packages [49]. Microarray data from the knockdown analysis
was submitted to GEO – accession number: GSE14543.
Affymetrix CEL files for i) five ESFT cell lines (TC252,
SKNMC, STA-ET-7.2, STA-ET-1, WE68, knockdown and
control), ii) expression experiments from 3 different datasets of
molecularly confirmed primary ESFT (Henderson et al. 2005:
n=5, Schaefer et al. 2008: n=27, Tirode et al. 2007: n=27,
[6,7,8] (ArrayExpress: E-MEXP-353), (ArrayExpress: E-MEXP-
1142), (GEO: GSE7007). and iii) the ‘‘Novartis gene expression
atlas’’ which comprises 79 tissues [13] (GEO: GSE1133) and iv)
mesenchymal progenitor cell data [8 (GEO: GSE7007),14
(ArrayExpress. E-MEXP-167)] were normalized together using
the gcrma logarithm [50]. For further analysis probesets (ps) were
called present or absent using the Bioconductor package ‘‘panp’’,
and ps were excluded which showed very low expression across all
arrays (P.0.05). Subsequently ps were excluded that did not pass
a non-stringent variability cut-off across the 10 EWS-FLI1 cell line
arrays (interquantile range.0.2). Thereby ps were excluded that
did not show variation in the EWS-FLI1 knock-down compared to
control experiments. Finally, for each gene one ps was selected for
further analysis by the criterion of maximizing the expression
variation across arrays and thereby the most informative ps was
chosen for each gene. This procedure yielded a final number of
7034 ps that were used for all further analysis. A list of used probe
sets can be found in Table S1.
Hypothesis free clustering of the 1000 most variable genes in the
data set shows that, despite being from three different sources,
ESFT form a group distinct from all other tissues that were
analyzed (Figure S1) and within this cluster ESFT from the three
sources are intermixed. This demonstrates that an often observed
‘‘batch effect’’ [51] does not distort the similarity pattern in this
data set. Furthermore the experiments from the five ESFT cell
lines are placed next to the primary tumors in the resulting
dendrogram further corroborating the biologically meaningful
clustering of samples.
Differentially expressed genes were determined using a moder-
ated t-test in the R package ‘‘limma’’ [52] and a non-parametric
method provided in the R package ‘‘RankProd’’ [53]. All P values
were corrected for multiple testing using the ‘‘Benjamini-Hoch-
berg’’ correction method. For the determination of significantly
changing genes in the EWS-FLI1 knock-down compared to control
experiments first ratios for each gene were calculated between the
two conditions for each cell line separately, thus yielding five
biological replicates of relative expression for each gene. Then for
each gene significance was determined using the equivalent of a
one-sample t-test in limma and RankProd. Using the same false
discovery rate, the resulting gene lists from both methods largely
overlapped and significant genes from both methods were
combined. To identify differently expressed genes between ESFT
and a reference, a two-sample moderated t-test was performed in
limma. ESFT samples from the three above mentioned sources
were averaged. For MPC, bone marrow mesenchymal progenitor
cell data from Tirode et al [8] and CD31-minus samples from
Boquest et al [14] were combined and for the tissues in the Novartis
gene atlas the two replicates for each tissue were averaged.
To select genes from gene sets differentially expressed in EWS-
FLI1 knockdown experiments (deltaKD) and in primary ESFT
(deltaET) for intersection, we deliberately chose two cut-offs of
different stringencies that would allow to maximize the number of
genes for functional annotation in GS1 and GS2 at a reasonably
significant p-value. Choosing thresholds (FDR) of 0.1 and 0.25
fulfilled this requirement by producing a large enough data set for
functional annotation, while the random expectation for a gene
being present in both deltaKD and deltaET data sets at these
thresholds is only 0.01 and 0.025, respectively.
Functional annotation
The ‘‘Database for Annotation, Visualization and Integrated
Discovery’’ (DAVID) was used to annotate the 344 up- and 237
downregulated genes of GS1. The ‘‘Functional Annotation Tool’’
in the online version of DAVID was run (http://david.abcc.
ncifcrf.gov/) using the default parameters and additionally protein
interaction data from the ‘‘BIND’’, ‘‘DIP’’, ‘‘MINT’’ and
‘‘NCICB_CAPATHWAY’’ as annotation databases. The ‘‘Func-
tional Annotation Clustering’’ tool was used to combine significant
annotation terms into functional groups (FG) using default
parameters. The output from this analysis can be found as
supplementary Table S2, S3. The genes for each FG in these
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data bases and the genes present in GS1.
Multidimensional scaling (MDS) and hierarchical
clustering (HC)
To visualize the relationships of the functional groups from the
functional annotation analysis (Table S2, S3) first similarity between
all groups was measured bythe number of theirshared genes (gDist).
For each pair of FGs gDist was calculated as gDist=N(A)>N(B)/
min(N(A), N(B)), where N(A) denotes the number of genes in FG (A).
Therefore, a similarity of 1 indicates that the smaller gene set is a
subset of the larger gene set. All genes of an FG were used for the
calculation.The matrix ofpair wisegDist values (as dissimilarities: 1-
gDist) for the 25 most significant FGs from DAVID was used as
input for MDS and HC. For MDS the R function ‘‘sammon’’ from
the R package MASS was used with default parameters. In brief, the
procedure, which is a form of non-metric multidimensional scaling,
iteratively attempts to place the samples (FGs) in n-dimensional
space to reflect their similarity as measured by gDist, while
minimizing the overall ‘‘Stress’’ statistic. This statistic is based on
the sum ofsquared differencesbetween theinput distances andthose
of the configuration. Therefore, it converges at an optimal solution
for visualizing similarity/dissimilarity of all samples inn-dimensional
space. Here a solution for two dimensions was sought. The
coordinates of the FGs on the first two axes (dimensions) of the
MDS are shown in Figure 3. Additionally, circles were drawn
around the coordinates of FGs were the size of the circles indicates
the relative size (number of genes) of the FGs. Therefore FGs with a
distance of 0 can be visualized.
For HC and the heatmap in Figure 3 the R function ‘‘hclust’’
was used in combination with the ‘‘heatmap.2’’ function using the
‘‘average linkage’’ algorithm. For the labels of the FGs in Figure 3,
the most significant annotation term within each FG was chosen
(see Table S2, S3).
pGSEA analysis
The gene set collections C1, C2, C3 of the MSigDB were
downloaded from the Broad institute (http://www.broad.mit.edu/
gsea/msigdb/) and loaded into R statistical environment. The
PGSEApackage[17] wasused tocalculatez-scoresforallgenesetsin
MgSigDB using the mean log2-foldchange for DKD and DET. All
significant MSigDB gene sets along with gene IDs can be found in
Table S4. For the identification of the ten most significant gene sets in
C2–C3 the sum of the absolute values of the two z-scores (for DKD or
DET) for each gene set was calculated and the gene IDs for highest
scoring gene sets were extracted. Based on the gene IDs of these gene
sets gDist was calculated for all pair wise combinations of up- and
downregulated gene sets separately. The resulting two matrices were
used asinputfor HC asdescribedabove. The two combined genelists
for up- and down regulated genes were also used as input for
functional annotation with DAVID as described above.
Supporting Information
Figure S1 Heatmap of the 1,000 most variable genes.
Variability of genes across samples was measured as standard
deviation. Hierarchical clustering was performed using ‘‘euclidian
distance’’ and ‘‘complete linkage.’’ The color bar on top of the
heatmap indicates the sample affiliations: Red - primary ESFT,
orange - ESFT cell lines (RNAi control), green - ESFT cell lines
(RNAi knockdown), blue - tissues from the Novartis gene
expression atlas. The color ramp white-yellow-orange-red is used
to display the log2 expression values (after gcrma normalization) of
each gene in each sample. Primary ESFT form a cluster
independent of the data source.
Found at: doi:10.1371/journal.pone.0005415.s001 (6.85 MB TIF)
Figure S2 Comparison with the Hancock et al 2008 EWS-FLI1
signature. Plot of relative gene expression values of the EWS-FLI1
knockdown compared to control (deltaKD, x-axis) and ESFT
compared to reference (deltaET, y-axis) for genes that were found
significant in Hancock et al 2008. (A) Genes found to be up-
regulated in the Hancock data set. (B) Genes found to be down-
regulated in the Hancock data set. Red/dark blue dots denote
genes that were found in GS1 in our study; Pink/light blue dots
denote genes that were found in GS2 in our study; Grey dots
denote genes that are neither in GS1 nor in GS2.
Found at: doi:10.1371/journal.pone.0005415.s002 (0.32 MB TIF)
Table S1 Differential expression - genelists. List of differential
expression values and annotation (DKD-DET) for all genes/
probesets and for subsets meeting significance level cutoffs (GS1,
GS2).
Found at: doi:10.1371/journal.pone.0005415.s003 (2.18 MB
XLS)
Table S2 DAVID Analysis - up. Output from DAVID analysis
for EWS-FLI1 upregulated genes in GS1.
Found at: doi:10.1371/journal.pone.0005415.s004 (0.30 MB
XLS)
Table S3 DAVID Analysis - down. Output from DAVID
analysis for EWS-FLI1 downregulated genes in GS1.
Found at: doi:10.1371/journal.pone.0005415.s005 (0.22 MB
XLS)
Table S4 pGSEA Analysis. Output from pGSEA analysis.
Found at: doi:10.1371/journal.pone.0005415.s006 (0.16 MB
XLS)
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